TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3966424

Group type: EXPERIMENTAL
Intervention: Oral zinc supplements
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31071484

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification, interpretation retraining (CBM‐I)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 69
Study: 30016467

Group type: EXPERIMENTAL
Intervention: methylphenidate (0.5 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 27555998

Group type: EXPERIMENTAL
Intervention: Cervical Disk Arthroplasty (CDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior Cervical Diskectomy and Fusion (ACDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ACDF)
Number of subjects: 0
Study: 24814857

Group type: EXPERIMENTAL
Intervention: DFPP combined with oral methylprednisolone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral methylprednisolone alone
Number of subjects: 35
Study: 22210565

Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Higher HbA(1c)
Number of subjects: 241
Study: 20083690

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) (595 nm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Potassium titanyl phosphate (KTP) laser (532 nm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrodesiccation
Number of subjects: 15
Study: 18036977

Group type: EXPERIMENTAL
Intervention: 12-week standard hospital rehabilitation program supplemented with an exercise-training program (n=11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 12-week standard rehabilitation program at home (n=9)
Number of subjects: 20
Study: 16651327

Group type: EXPERIMENTAL
Intervention: Azithromycin (12 mg/kg per day, up to a maximum of 500 mg/day) for 5 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 13130174

Group type: EXPERIMENTAL
Intervention: 30-45 min of physiotherapy twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maximally 15 min of physiotherapy per day for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups received dexamphetamine to achieve alertness
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increased intensity of physiotherapy combined with dexamphetamine
Number of subjects: 30
Study: 10998029

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 23

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 23
Study: 8868605

Group type: EXPERIMENTAL
Intervention: En-bloc-esophagectomy (EB)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transhiatal blunt esophagectomy with dissection of all reachable lymph nodes (ESD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Systematic dissection (SD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Blunt dissection
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups (SD, ESD, EB)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Negative lymph node involvement
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Positive lymph node involvement
Number of subjects: 26
Study: 1519783

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (8 micrograms.kg‐1 in 4 ml over 2 min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (8 micrograms.kg‐1 in 10 ml over 14 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Epidural saline (4 ml over 2 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous saline (10 ml over 14 min)
Number of subjects: 18
Study: 6227643

Group type: EXPERIMENTAL
Intervention: 3% erythromycin and 5% benzoyl peroxide combination gel
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 3% erythromycin gel
Number of subjects: 165

Group type: COMPARATOR
Intervention: gel vehicle
Number of subjects: 165
Study: 30912475

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 28644740

Group type: EXPERIMENTAL
Intervention: Behavioural activation
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 59
Study: 26458917

Group type: EXPERIMENTAL
Intervention: MATCH‐ADTC
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 23426342

Group type: EXPERIMENTAL
Intervention: VR simulation training
Number of subjects: 225
Study: 20305057

Group type: EXPERIMENTAL
Intervention: Biolimus A9 (BA9) at doses from 0.0075 mg/kg to 0.25 mg/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Biolimus A9 (BA9)
Number of subjects: 28
Study: 19930788

Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray (2 sprays/nostril twice daily)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Azelastine 0.10% nasal spray (2 sprays/nostril twice daily)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% and 0.10% nasal sprays
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Azelastine 0.15%
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Azelastine 0.10%
Number of subjects: 526
Study: 17197583

Group type: EXPERIMENTAL
Intervention: Uterine leiomyoma embolization
Number of subjects: 66

Group type: COMPARATOR
Intervention: Laparoscopic occlusion of uterine arteries
Number of subjects: 66
Study: 15636168

Group type: EXPERIMENTAL
Intervention: Cecropia obtusifolia
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Marrubium vulgare
Number of subjects: 43
Study: 11716226

Group type: EXPERIMENTAL
Intervention: Concomitant methotrexate and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy in oropharyngeal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiation (unspecified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of methotrexate with radiotherapy
Number of subjects: 0
Study: 9205339

Group type: EXPERIMENTAL
Intervention: Information given to patients in their own home before admission and again on their first day in hospital.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 40
Study: 7957366

Group type: EXPERIMENTAL
Intervention: Artificial surfactant (Exosurf)
Number of subjects: 44
Study: 2442536

Group type: EXPERIMENTAL
Intervention: Bornaprolol 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bornaprolol 80 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bornaprolol 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bornaprolol 240 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bornaprolol 480 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bornaprolol 960 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bornaprolol (various doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29807824

Group type: EXPERIMENTAL
Intervention: 1·1 GBq radioactive iodine after rhTSH
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: 3·7 GBq radioactive iodine after rhTSH
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: 1·1 GBq radioactive iodine after thyroid hormone withdrawal
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: 3·7 GBq radioactive iodine after thyroid hormone withdrawal
Number of subjects: 726
Study: 27869576

Group type: EXPERIMENTAL
Intervention: Messages with visual and textual metaphors
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Messages with straightforward visuals and textual metaphors
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Text-based metaphor messages
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 256
Study: 25019111

Group type: EXPERIMENTAL
Intervention: Bromelain
Number of subjects: 80

Group type: COMPARATOR
Intervention: Analgesic (only if required)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (analgesic only)
Number of subjects: 80
Study: 22246515

Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health-promotion control
Number of subjects: 0
Study: 19941694

Group type: EXPERIMENTAL
Intervention: Mirtazapine (n=19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 37
Study: 18272475

Group type: EXPERIMENTAL
Intervention: S-1 (80 mg/m²/day for four weeks, repeated every six weeks for a total of four courses)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² on days 1, 8, and 15, repeated every four weeks for a total of six courses)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 360

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 360
Study: 16524650

Group type: EXPERIMENTAL
Intervention: Principal component analysis of kinetic lifting waveforms
Number of subjects: 0
Study: 14631184

Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 1
Study: 10627101

Group type: EXPERIMENTAL
Intervention: CMCA intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 9420113

Group type: EXPERIMENTAL
Intervention: CAGE screening test
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Brief Michigan Alcoholism Screening Test
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Structured Clinical Interview
Number of subjects: 1118
Study: 1286495

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.7 mg, intravenously)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 4023558

Group type: EXPERIMENTAL
Intervention: Praziquantel therapy
Number of subjects: 45
Study: 31810023

Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 704

Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 704
Study: 30475957

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet (5 days without energy restriction and 2 days with 75% energy deficit)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continuous Calorie Restriction (CCR) - daily energy deficit ∼20%
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group - no advice to restrict energy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continuous Calorie Restriction (CCR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 28749419

Group type: EXPERIMENTAL
Intervention: 28 g of whole, lightly salted roasted almonds
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isoenergetic baked food
Number of subjects: 22
Study: 26785372

Group type: EXPERIMENTAL
Intervention: BCAA + OA supplementation (16 g BCAA and 12 g OA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Flavoured water (placebo)
Number of subjects: 11
Study: 21783387

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose Flutamide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21226758

Group type: EXPERIMENTAL
Intervention: Manual therapy and child physiotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Child physiotherapy alone
Number of subjects: 32
Study: 18192850

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 16
Study: 16644641

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12851191

Group type: EXPERIMENTAL
Intervention: Safehip hip protectors
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 366
Study: 10823258

Group type: EXPERIMENTAL
Intervention: Weekly self-testing and self-dosing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 102
Study: 8877665

Group type: EXPERIMENTAL
Intervention: Triclosan-containing mouthrinses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 30
Study: 1739562

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg kg‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6337988

Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg three times daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amoxycillin 500 mg three times daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cefaclor and Amoxycillin
Number of subjects: 80
Study: 31187506

Group type: EXPERIMENTAL
Intervention: Romantic rejection by desired dating partners (for males)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Romantic rejection by desired dating partners (for females)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased feelings of anger (for males)
Number of subjects: 0
Study: 28612671

Group type: EXPERIMENTAL
Intervention: MgSO4
Number of subjects: 1894

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1894
Study: 27596244

Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-led intervention including a pillbox, Blue-toothed UA-767Plus BT BP device, and smartphone for monitoring BP and medication intake under nurse guidance for 3 months.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-led intervention.
Number of subjects: 60
Study: 24526821

Group type: EXPERIMENTAL
Intervention: ω-3 PUFAs supplementation (docosahexaenoic acid 71.9 ± 13.9 mg/kg b.w./day plus eicosapentaenoic acid 115.5 ± 22.4 mg/kg b.w./day) for 12 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Untreated population (Control)
Number of subjects: 66
Study: 20716324

Group type: EXPERIMENTAL
Intervention: Silicone diffractive multifocal IOL (Tecnis ZM900)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Acrylic diffractive multifocal IOL (Tecnis ZMA00)
Number of subjects: 21
Study: 21029001

Group type: EXPERIMENTAL
Intervention: Azelnidipine 8‐16 mg/day
Number of subjects: 220

Group type: COMPARATOR
Intervention: Amlodipine 2.5‐5 mg/day
Number of subjects: 220
Study: 16985182

Group type: COMPARATOR
Intervention: Regimen A (doxorubicin, vincristine, cyclophosphamide, dactinomycin)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Regimen B (doxorubicin, vincristine, cyclophosphamide, dactinomycin alternating with etoposide and ifosfamide)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Regimen C (high-intensity therapy with higher doses of doxorubicin, cyclophosphamide, and ifosfamide)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Increasing exposure to ifosfamide (90 to 140 g/m2), cyclophosphamide (9.6 to 17.6 g/m2), and doxorubicin (375 to 450 mg/m2)
Number of subjects: 578
Study: 16358235

Group type: EXPERIMENTAL
Intervention: Cefotaxime-heparin lock solution
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 208
Study: 12028163

Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU) treatment
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (traditional treatment in Department of Internal Medicine)
Number of subjects: 254
Study: 11176980

Group type: EXPERIMENTAL
Intervention: Verteporfin
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Verteporfin (predominantly classic lesions)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo (predominantly classic lesions)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Verteporfin (minimally classic lesions)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo (minimally classic lesions)
Number of subjects: 609
Study: 9145823

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg od for 10 days
Number of subjects: 411

Group type: COMPARATOR
Intervention: Doxycycline 100 mg bd for 10 days
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 411

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 411
Study: 7967272

Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (CWBC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intermittent cold GIK cardioplegia (ICGC)
Number of subjects: 24
Study: 3480076

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cefoxitin/Doxycycline
Number of subjects: 50
Study: 29204924

Group type: EXPERIMENTAL
Intervention: Bleomycin microneedle patch
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 42
Study: 26944837

Group type: EXPERIMENTAL
Intervention: Short-acting β-agonists
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Daily maintenance medications
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Asthma action plan
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Assessment of control
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Inhaler technique education
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Medication adherence assessment
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Allergy evaluation
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: No asthma-related visit in the year before enrollment
Number of subjects: 1176
Study: 25509976

Group type: EXPERIMENTAL
Intervention: Intracervical anesthesia (10 ml %2 prilocaine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 200
Study: 23589143

Group type: EXPERIMENTAL
Intervention: Liquid nutrient meal (LNM; Ensure Plus(®))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solid meal (egg‐white sandwich, EWS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC; SmartPill(®))
Number of subjects: 20
Study: 20803165

Group type: EXPERIMENTAL
Intervention: Behavioral prescription to read the self-help book, Feeling Good
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care treatment for depression (often involves medication)
Number of subjects: 38
Study: 19469296

Group type: EXPERIMENTAL
Intervention: Morphine 0.5 mg/ml + ketamine 0.5 mg/ml (MK-group)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Morphine 0.5 mg/ml + placebo (M-group)
Number of subjects: 138
Study: 16243243

Group type: EXPERIMENTAL
Intervention: 1.25% or 2.5% ethanolamine oleate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study: 12522747

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg intravenously or orally every 12 h)
Number of subjects: 796
Study: 10659081

Group type: EXPERIMENTAL
Intervention: Full attention condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divided attention condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion task with memory strategies
Number of subjects: 0
Study: 8681490

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg nicotine per piece, at least six pieces per day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 29
Study: 1947721

Group type: EXPERIMENTAL
Intervention: Insulin infusion (2 mU kg‐1 min‐1) with volume expansion (2 L isotonic sodium chloride) for 2 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insulin infusion without volume expansion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined hyperinsulinaemia and volume expansion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (Day B: no insulin and glucose infusion)
Number of subjects: 6
Study: 31136288

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 2598

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering
Number of subjects: 2598
Study: 29023178

Group type: EXPERIMENTAL
Intervention: Aquamin F™ (derived from Lithothamnion sp.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26466128

Group type: EXPERIMENTAL
Intervention: Custom-made (CM) mouthguard
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard (BB) mouthguard
Number of subjects: 10

Group type: COMPARATOR
Intervention: No mouthguard (CON)
Number of subjects: 10
Study: 27128612

Group type: EXPERIMENTAL
Intervention: MF 800 µg + F 20 µg coadministered (MF + F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MF 800 µg/F 20 µg (MF/F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MF 800 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: F 20 µg
Number of subjects: 0
Study: 22139393

Group type: EXPERIMENTAL
Intervention: Spinal orthosis (Thämert Osteo-med)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 69
Study: 20702114

Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (topical nitrate only when SBP ≥220 mm Hg or DBP ≥120 mm Hg)
Number of subjects: 40
Study: 17211270

Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 U) given subcutaneously once daily for 6 weeks postoperatively
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15882789

Group type: EXPERIMENTAL
Intervention: Unidirectional task
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bidirectional task
Number of subjects: 10
Study: 12210616

Group type: EXPERIMENTAL
Intervention: Network meta-analysis techniques for treatment comparisons
Number of subjects: 0
Study: 9589308

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0